$REGN Headlines Sprint gains on narrower loss; WPX tops

New Post Public Reply Private Reply Replies (0) Message Board

Feb 27, 2014 at 10:57 AM

$REGN Headlines

Sprint gains on narrower loss; WPX tops S&P 500 losers 4:15 p.m. Feb. 11, 2014 - Sue Chang
Dow nabs best gain of year after Yellen remarks, debt-ceiling news: stock market live blog recap 3:55 p.m. Feb. 11, 2014 - blogs.marketwatch.com
Regeneron diabetic eye remedy does well in trial 8:02 a.m. Feb. 10, 2014 - MarketWatch.com
Stocks stabilize; now it’s up to Yellen, the consumer 8:01 a.m. Feb. 9, 2014 - Wallace Witkowski
Tesla extends gains; ExOne sinks on revenue warning 3:45 p.m. Jan. 15, 2014 - Sue Chang
GameStop tumbles 20%; Tesla surges on strong sales 4:23 p.m. Jan. 14, 2014 - Sue Chang
Regeneron climbs by double-digits, leads S&P after presentation 3:58 p.m. Jan. 14, 2014 - Russ Britt
Dow jumps 116 points, best day this year: Stock market live blog recap 3:51 p.m. Jan. 14, 2014 - blogs.marketwatch.com
Three biopharma companies poised for product OKs in 2014: analyst 12:51 p.m. Jan. 6, 2014 - Russ Britt
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Apple off on market data, Twitter down as options debut 4:36 p.m. Nov. 15, 2013 - Sue Chang
Macy's, Potbelly gain; Chegg slumps in debut 5:04 p.m. Nov. 13, 2013 - Sue Chang
GT spikes on sapphire deal with Apple 4:45 p.m. Nov. 5, 2013 - Sue Chang
Regeneron shares near $300 as earnings report emboldens investors 11:14 a.m. Nov. 5, 2013 - Russ Britt
The next big pharma 6:01 a.m. Oct. 25, 2013 - The Trading Deck
Apple extends gains on price target hike 2:47 p.m. Oct. 16, 2013 - Sue Chang
Apple gains on upgrade; BlackBerry rallies 3:34 p.m. Oct. 7, 2013 - Sue Chang
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
J.C. Penney sinks to lowest level since 1982 3:23 p.m. Sept. 30, 2013 - Sue Chang
Device firms, Regeneron see gains while general markets fear shutdown 12:36 p.m. Sept. 30, 2013 - Russ Britt

Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog 10:26 a.m. Feb. 26, 2014 - Zacks.com
Insider Trading Alert - WDC, REGN And POWI Traded By Insiders 10:15 a.m. Feb. 26, 2014 - TheStreet.com
Sanofi/Ardelyx Ink Deal - Analyst Blog 7:00 p.m. Feb. 25, 2014 - Zacks.com
3 Stocks Pushing The Health Care Sector Lower 12:02 p.m. Feb. 25, 2014 - TheStreet.com
No Looking Back for Regeneron's Eylea - Analyst Blog 11:08 a.m. Feb. 25, 2014 - Zacks.com
Hold Recommendation Reiterated For Regeneron Pharmaceuticals Inc. 9:00 a.m. Feb. 25, 2014 - TheStreet.com
Cramer's Mad Money - 15 Momentum Monsters (2/24/14) 6:25 a.m. Feb. 25, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: The Values Are Out There 8:06 p.m. Feb. 24, 2014 - TheStreet.com
Insider Trading Alert - KMI, REGN And DRH Traded By Insiders 10:30 a.m. Feb. 24, 2014 - TheStreet.com
Today Regeneron Pharmaceuticals (REGN) Hits New Lifetime High 9:45 a.m. Feb. 24, 2014 - TheStreet.com
FDA accepts Regeneron filing to widen use of Eylea 9:18 a.m. Feb. 24, 2014 - Seeking Alpha
UPDATE: Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion 6:32 a.m. Feb. 24, 2014 - benzinga.com
Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner 5:00 p.m. Feb. 21, 2014 - TheStreet.com
Regeneron Pharmaceuticals, Inc. (REGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Feb. 21, 2014 - Zacks.com
REGN, BIIB And CELG, Pushing Drugs Industry Downward 12:04 p.m. Feb. 19, 2014 - TheStreet.com
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog 9:27 a.m. Feb. 19, 2014 - Zacks.com
6 Biotechnology Stocks to Buy Now 2:30 a.m. Feb. 19, 2014 - InvestorPlace.com
Biotech Remains on Fast Track 11:00 a.m. Feb. 18, 2014 - RealMoney.com
pSivida: Positive Roche And Regeneron Conference Calls Confirm Tehadur's Potential 8:39 a.m. Feb. 18, 2014 - Seeking Alpha
Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA 9:51 a.m. Feb. 17, 2014 - GuruFocus.com

Critical Alerts For Walter Energy, Regeneron, Biogen Idec, Red Hat, and Level 3 Communications Released By InvestorsObserver 9:31 a.m. Today - PR Newswire - PRF
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion 7:30 a.m. Feb. 24, 2014 - PR Newswire - PRF
Regeneron Announces Upcoming 2014 Investor Conference Presentations 9:30 a.m. Feb. 14, 2014 - PR Newswire - PRF
Regeneron Reports Fourth Quarter and Full Year 2013 Financial and Operating Results 6:30 a.m. Feb. 11, 2014 - PR Newswire - PRF
Two-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision 7:30 a.m. Feb. 10, 2014 - PR Newswire - PRF
Critical Alerts For Intel, Regeneron, Lowes, eBay, and KB Homes Released By InvestorsObserver 9:31 a.m. Jan. 23, 2014 - PR Newswire - PRF
Regeneron to Report Fourth Quarter and Full Year 2013 Financial and Operating Results and Host Conference Call and Webcast on February 11, 2014 9:30 a.m. Jan. 21, 2014 - PR Newswire - PRF
Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration 4:05 p.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron and Geisinger Health System Announce Major Human Genetics Research Collaboration 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron Launches New Human Genetics Initiative 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Regeneron Announces Amendment to Investor Agreement with Sanofi 2:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Upcoming Presentations and Stock Price Movements - Research Report on Bard, Regeneron, Alexion, Seattle Genetics, and Isis Pharmaceuticals 8:00 a.m. Jan. 9, 2014 - PR Newswire
Clinical Study Updates, Collaborations, and Stock Price Updates - Research Report on Medtronic, Regeneron, Celldex, Cubist, and MannKind 8:00 a.m. Dec. 31, 2013 - PR Newswire
Critical Alerts For Stratasys, Regeneron, Ctrip, Paychex, and Tyson Released By InvestorsObserver 9:31 a.m. Dec. 23, 2013 - PR Newswire
Regulatory Updates, Clinical Trial Results, and Stock Price Movements - Research Report on Johnson & Johnson, Cubist, Regeneron, Medtronic, and Jazz Pharmaceuticals 8:00 a.m. Dec. 19, 2013 - PR Newswire
Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program 1:00 a.m. Dec. 19, 2013 - PR Newswire
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication 7:30 a.m. Dec. 18, 2013 - PR Newswire
Regeneron Announces Presentation at the 32nd Annual J. P. Morgan Healthcare Conference 9:30 a.m. Dec. 17, 2013 - PR Newswire
New Clinical Trials, Pricing of Common Stock and Adjusted Conversion of Convertible Senior Notes - Research Report on Regeneron, Celldex, PDL BioPharma, Amedisys, and Exelixis 8:00 a.m. Dec. 11, 2013 - PR Newswire
Regeneron Announces Upcoming 2013 Investor Conference Presentation 9:30 a.m. Dec. 4, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Horowitz's $150M Boost for Nevada's First Children's Hospital

Big Bucks and Bigger Hearts Boost Pediatric Care in Nevada The world isn't exactly short on folks looking to make a buck, but every so often, someone comes along and wants to make a difference instead. Enter Felicia and Ben Horowitz, handing over a staggering $150 million to Intermountain Health. This isn’t your garden-variety gift—it’s aimed at getting Nevada on...

UCB's Endowment Marks New Era in Medicine Evaluation

Stepping into a New Chapter for Medicine Evaluation UCB's latest move smacks of a strategic vision that's not just about immediate returns—it's a long game in pharmacoepidemiology. You don't see investors lining up for this news, but this chair at Brigham and Women's is bigger than it looks. By establishing the Emmanuel Janssen Endowed Chair, UCB is underpinning the...

Steady Income Boosts FHLBank Boston's Growth Q3 2026

The Federal Home Loan Bank of Boston dropped their third-quarter results for 2026 like a hot smokestack, and let me tell you, it's a mixed bag of cautious optimism and steady progression. It's essentially proof that slow and steady might just win the race—or at least keep you in the running. Stable and Steady Headway Taking a peek under the hood, FHLBank Boston made a...

Wisconsin Brats Clash with Florida Citrus in Marketing Showdown

A Juicy Rivalry with Sweet and Savory Stakes You ever catch yourself watching state pride turn into a marketing showdown? That's what's cookin' with Wisconsin's Johnsonville and Florida's Natural, and believe me, this isn't just about what’s on your plate. Forget the foam fingers, here it's all about the brats and the OJ. It's like the Packers versus the Dolphins, but...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Patrick Ta Beauty Adds New Leadership to Expand Growth

Angela Simpson and Carolyne Rapp Join the Ranks In the fast-paced world of beauty, where trends shift faster than a day trader’s mood, Patrick Ta Beauty is shaking things up with some heavyweight hires. Angela Simpson steps in as Chief Marketing Officer, and Carolyne Rapp takes the reins as Vice President of Creative. Maybe it’s just me, but when a brand ropes in pros...

Lunit, Summit Tackle Tumor Analysis with AI Platform

Amid whispers of AI revolutionizing every industry, let's zero in on its latest pit stop—oncology R&D. Lunit, shaking hands with Summit Therapeutics, plans to bring artificial intelligence into the tumor microenvironment analysis game, thanks to the Lunit SCOPE IO platform. This isn't just another lab experiment; it's a step towards redefining how we understand cancer's...

Hyperliquid Reports Q3 2026 Results with Webcast Insights

Unlocking Hyperliquid’s Third Quarter Performance It's time to grab your investing gear because Hyperliquid Strategies Inc is ready to spill the beans on their Q3 2026 performance. The digital asset treasury focused on the hyperventilating HYPE token—fined-tuned to serve US and institutional investors—is broadcasting a live webcast on November 5, 2026. Mark your...

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Veterans Find Community and Wellness at Orland Hills Bash

A Celebration of Veterans and Community Orland Hills is set to light up with a unique Veterans Day Bash on November 1, 2026. This isn't just your run-of-the-mill community gathering; it's an event that brings together veterans from all around for a day packed with resources, education, and a chance to connect with kindred spirits—all thanks to the collaboration between...